medigraphic.com
A partir del año 2010, la Revista Oficial del INER cambió a NCT (Neumología y Cirugía de Tórax)

 Ver actualización

2006, Number 4

<< Back Next >>

Rev Inst Nal Enf Resp Mex 2006; 19 (4)

Evidence for the use of methylxantines in exacerbations of COPD

Arellano MJ, García GML

Language: Spanish
References: 11
Page: 309-315
PDF size: 89.74 Kb.


ABSTRACT

Introduction: Methylxantines are used for stable chronic obstructive pulmonary disease (COPD), when there is need for an additional drug besides Β2 agonists and anticholinergics, in the more advanced stages of the disease and during acute exacerbations. Among other effects, methylxantines are said to have bronchodilator properties.
Objective: To review the evidence supporting the use of methylxantines during acute exacerbations of COPD , and the presence of other beneficial properties besides their bronchodilator effects.
Method: Medline and EMBASE computer search for aleatorized controlled studies comparing methylxantines (oral theophylline, intravenous aminophylline or doxophylline) vs placebo.
Results: Only five of 1,356 published studies fulfilled the inclusion criteria. The evidence showed no significant improvement in FEV1; only one study showed a 70 vs 40 mL improvement on day 3; there was also decrease in the PCO2 and slight increase in the pH 12 hours after the use of aminophylline. There was no significant improvement in length of stay, quality of life nor dyspnoea scales. Nausea and vomiting were more frequent in the methylxantine group.
Conclusions: We need properly structured protocols with statistically significant results, to define the evidence based place for the use of methylxantines in the treatment of acute exacerbations of COPD.


REFERENCES

  1. Barnes PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 2003;167:813-818.

  2. ZuWallack AR. Theophylline and phosphodiesterase inhibitors in COPD. In: Celli BR, editor. Pharmacotherapy in chronic obstructive pulmonary disease. Lung Biology in Health & Disease, Vol. 182. New York: Marcel Dekker;2004. p. 239-263.

  3. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2004. Based on an April 1998 NHLBI/WHO Workshop. Disponible en: http://www.goldcopd.org

  4. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946.

  5. British Thoracic Society guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the British Thoracic Society. Thorax 1997;52 (Suppl 5):S1-S28.

  6. Guías para el Diagnóstico y el Tratamiento de la Enfermedad Pulmonar Obstructiva Crónica. Derivadas del Segundo Consenso Mexicano para el Diagnóstico y Tratamiento del EPOC. Edición especial. México, DF:INER, SMNCT; 2003.

  7. Seindenfeld JJ, Jones WN, Moss RE, Tremper J. Intravenous aminophylline in the treatment of acute bronchospastic exacerbations of chronic obstructive pulmonary disease. Ann Emerg Med 1984;13:248-252.

  8. Rice KL, Leatherman JW, Duane PG, et al. Aminophylline for acute exacerbations of chronic obstructive pulmonary disease: a controlled trial. Ann Intern Med 1987;107:305-309.

  9. Wrenn K, Slovis CM, Murphy F, Greenberg RS. Aminophylline therapy for acute bronchospastic disease in the emergency room. Ann Intern Med 1991;115: 241-247.

  10. Ram FSF, Poole PJ, Bagg W, Stewart, Black PN. Randomized, controlled trial of oral theophylline for the treatment of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161 (Suppl):A489.

  11. Duffy N, Walker P, Diamantea F, Calverley MA, Davies L. Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Thorax 2005;60:713-717.




2020     |     www.medigraphic.com